Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Targeted therapies have improved outcomes in myelofibrosis (MF).
• Evidence demonstrating modification of MF's natural history by new agents is limited.
• Unmet therapeutic needs persist in MF treatment.

Purpose of the Study:

• To outline key considerations for future clinical trials in myelofibrosis.
• To emphasize the importance of overall survival (OS) as a primary endpoint.
• To highlight the need for improved methods to assess disease progression and patient-reported outcomes (PROs).

Main Methods:

• Review of current therapeutic landscape and clinical trial designs in MF.
• Discussion of optimal patient populations and trial designs for next-generation studies.
• Emphasis on incorporating patient-reported outcomes (PROs) and biomarkers.

Main Results:

• Substantial improvements in MF outcomes observed with new targeted therapies.
• Lack of robust data on the modification of MF's natural disease course.
• Identification of critical areas for future clinical trial development.

Conclusions:

• Future myelofibrosis trials must prioritize overall survival (OS) and disease progression endpoints.
• Incorporating patient-reported outcomes (PROs) and biomarkers is crucial for advancing MF research.
• Careful trial design and patient selection are essential for demonstrating meaningful clinical benefit.